Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma

  • Technology appraisal guidance
  • TA321
  • Published: 
Download guidance (PDF)

1 Recommendations

This guidance was developed using the single technology appraisal (STA) process.

1.1

Dabrafenib is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma only if the company provides dabrafenib with the discount agreed in the patient access scheme.